FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766702959> ?p ?o ?g. }

• W2766702959 endingPage "406" @default.
• W2766702959 startingPage "395" @default.
• W2766702959 abstract "Purpose: Therapeutic strategies against hormonal receptor-positive (HR+)/HER2+ breast cancers with poor response to trastuzumab need to be optimized.Experimental Design: Two HR+/HER2+ patient-derived xenograft (PDX) models named as COH-SC1 and COH-SC31 were established to explore targeted therapies for HER2+ breast cancers. RNA sequencing and RPPA (reverse phase protein array) analyses were conducted to decipher molecular features of the two PDXs and define the therapeutic strategy of interest, validated by in vivo drug efficacy examination and in vitro cell proliferation analysis.Results: Estrogen acted as a growth driver of trastuzumab-resistant COH-SC31 tumors but an accelerator in the trastuzumab-sensitive COH-SC1 model. In vivo trastuzumab efficacy examination further confirmed the consistent responses between PDXs and the corresponding tumors. Integrative omics analysis revealed that mammalian target of rapamycin (mTOR) and ERα signaling predominantly regulate tumor growth of the two HR+/HER2+ PDXs. Combination of the dual mTOR complex inhibitor MLN0128 and anti-HER2 trastuzumab strongly suppressed tumor growth of COH-SC1 PDX accompanied by increasing ER-positive cell population in vivo Instead, MLN0128 in combination with antiestrogen fulvestrant significantly halted the growth of HR+/HER2+ cancer cells in vitro and trastuzumab-resistant COH-SC31 as well as trastuzumab-sensitive COH-SC1 tumors in vivoConclusions: Compared with the standard trastuzumab treatment, this study demonstrates alternative therapeutic strategies against HR+/HER2+ tumors through establishment of two PDXs coupled with integrative omics analyses and in vivo drug efficacy examination. This work presents a prototype of future co-clinical trials to tailor personalized medicine in clinical practice. Clin Cancer Res; 24(2); 395-406. ©2017 AACR." @default.
• W2766702959 created "2017-11-10" @default.
• W2766702959 creator A5003378933 @default.
• W2766702959 creator A5005344580 @default.
• W2766702959 creator A5008908680 @default.
• W2766702959 creator A5013168935 @default.
• W2766702959 creator A5019000006 @default.
• W2766702959 creator A5021146685 @default.
• W2766702959 creator A5047098889 @default.
• W2766702959 creator A5049834756 @default.
• W2766702959 creator A5064649529 @default.
• W2766702959 creator A5074662779 @default.
• W2766702959 creator A5075719256 @default.
• W2766702959 creator A5077349136 @default.
• W2766702959 creator A5079121091 @default.
• W2766702959 creator A5081082858 @default.
• W2766702959 creator A5084717592 @default.
• W2766702959 date "2018-01-15" @default.
• W2766702959 modified "2023-10-09" @default.
• W2766702959 title "Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant" @default.
• W2766702959 cites W1494244942 @default.
• W2766702959 cites W1649914760 @default.
• W2766702959 cites W1830454849 @default.
• W2766702959 cites W1834339553 @default.
• W2766702959 cites W1873528488 @default.
• W2766702959 cites W1873831426 @default.
• W2766702959 cites W1983698019 @default.
• W2766702959 cites W1992312579 @default.
• W2766702959 cites W1997381761 @default.
• W2766702959 cites W2000895026 @default.
• W2766702959 cites W2007617935 @default.
• W2766702959 cites W2012672176 @default.
• W2766702959 cites W2016725598 @default.
• W2766702959 cites W2023247746 @default.
• W2766702959 cites W2025935112 @default.
• W2766702959 cites W2029281176 @default.
• W2766702959 cites W2031131661 @default.
• W2766702959 cites W2035825064 @default.
• W2766702959 cites W2056390240 @default.
• W2766702959 cites W2064823103 @default.
• W2766702959 cites W2080127092 @default.
• W2766702959 cites W2080238287 @default.
• W2766702959 cites W2086224272 @default.
• W2766702959 cites W2095949683 @default.
• W2766702959 cites W2098912234 @default.
• W2766702959 cites W2101979288 @default.
• W2766702959 cites W2106286200 @default.
• W2766702959 cites W2116987618 @default.
• W2766702959 cites W2124358769 @default.
• W2766702959 cites W2130642180 @default.
• W2766702959 cites W2132619562 @default.
• W2766702959 cites W2138832277 @default.
• W2766702959 cites W2147299492 @default.
• W2766702959 cites W2150134401 @default.
• W2766702959 cites W2151082560 @default.
• W2766702959 cites W2155127143 @default.
• W2766702959 cites W2159938731 @default.
• W2766702959 cites W2163750567 @default.
• W2766702959 cites W2168086498 @default.
• W2766702959 cites W2168133196 @default.
• W2766702959 cites W2168839110 @default.
• W2766702959 cites W2170181527 @default.
• W2766702959 cites W2289095709 @default.
• W2766702959 cites W319682692 @default.
• W2766702959 cites W4231018668 @default.
• W2766702959 cites W4234081105 @default.
• W2766702959 doi "https://doi.org/10.1158/1078-0432.ccr-17-1983" @default.
• W2766702959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29079660" @default.
• W2766702959 hasPublicationYear "2018" @default.
• W2766702959 type Work @default.
• W2766702959 sameAs 2766702959 @default.
• W2766702959 citedByCount "14" @default.
• W2766702959 countsByYear W27667029592018 @default.
• W2766702959 countsByYear W27667029592019 @default.
• W2766702959 countsByYear W27667029592020 @default.
• W2766702959 countsByYear W27667029592021 @default.
• W2766702959 countsByYear W27667029592023 @default.
• W2766702959 crossrefType "journal-article" @default.
• W2766702959 hasAuthorship W2766702959A5003378933 @default.
• W2766702959 hasAuthorship W2766702959A5005344580 @default.
• W2766702959 hasAuthorship W2766702959A5008908680 @default.
• W2766702959 hasAuthorship W2766702959A5013168935 @default.
• W2766702959 hasAuthorship W2766702959A5019000006 @default.
• W2766702959 hasAuthorship W2766702959A5021146685 @default.
• W2766702959 hasAuthorship W2766702959A5047098889 @default.
• W2766702959 hasAuthorship W2766702959A5049834756 @default.
• W2766702959 hasAuthorship W2766702959A5064649529 @default.
• W2766702959 hasAuthorship W2766702959A5074662779 @default.
• W2766702959 hasAuthorship W2766702959A5075719256 @default.
• W2766702959 hasAuthorship W2766702959A5077349136 @default.
• W2766702959 hasAuthorship W2766702959A5079121091 @default.
• W2766702959 hasAuthorship W2766702959A5081082858 @default.
• W2766702959 hasAuthorship W2766702959A5084717592 @default.
• W2766702959 hasBestOaLocation W27667029591 @default.
• W2766702959 hasConcept C121608353 @default.
• W2766702959 hasConcept C126322002 @default.
• W2766702959 hasConcept C143998085 @default.
• W2766702959 hasConcept C150903083 @default.

• next